Home
Our Science
Our Clinical Trial
About Us
News & Events
Contact Us
More
K36 Therapeutics announces dosing of first patient in KTX-1001 Phase 1 Clinical Trial for relapsed or refractory multiple myeloma and addition of Mr. Michael Heffernan as Independent Board Director
K36 Therapeutics Treats First Multiple Myeloma Patient in Phase I Trial of KTX-1001
F-Prime, Atlas back K36 with $30M to advance MM candidate
Atlas, F-Prime launch K36 Therapeutics to advance oncology molecule for elusive epigenetic target
Four Fresh-Faced Biopharmas Reel in Millions in Series A Funds
K36 Therapeutics Launches with $30 Million Series A Financing from F-Prime Capital and Atlas Venture with Eight Roads Ventures
K36 emerges with $30M to bankroll multiple myeloma drug in-licensed from Novartis
K36 Therapeutics Launches with $30 Million Series A Financing to Advance Targeted Therapy for Multiple Myeloma
K36 Therapeutics Raises $30M in Series A Funds
K36 Therapeutics Launches with $30 Million to Target Multiple Myeloma
Finance Watch: Four New VC Funds Provide $1.3bn For Biotech Start-Ups
Cancer therapeutics startup launches with $30M
